Case Study: Downstream Processing of Monoclonal Antibodies in Bioreactors

Added:

Protein A-Free and Non-Chromatographic Downstream Processing

While Protein A affinity chromatography is the industry gold standard for monoclonal antibody (mAb) purification due to its high selectivity, it presents significant drawbacks. These include extremely high resin costs, the risk of immunogenic ligand leaching, and the requirement for harsh, low-pH elution conditions that can compromise mAb stability and cause aggregation. A strong counter-perspective advocates for replacing Protein A with alternative technologies, such as polyelectrolyte precipitation, crystallization, aqueous two-phase systems (ATPS), and ion-exchange membrane chromatography. Proponents of these alternative methods argue they offer dramatically lower raw material costs, eliminate ligand contamination risks, and provide milder processing conditions. Transitioning away from traditional Protein A chromatography is increasingly viewed as a necessary step to achieve truly cost-effective, high-throughput, and continuous biomanufacturing.

Fundamental structure and function of monoclonal antibodies (mAbs), including the significance of the Fc region in binding.
Basic principles of upstream bioprocessing, including host cell expression systems (such as CHO cells) and bioreactor harvesting.
General chromatography principles, specifically liquid chromatography, stationary/mobile phases, and affinity-based separation.
Basic protein biochemistry, including protein stability, denaturation, aggregation, and the effect of pH and ionic strength on protein structure.
Advanced polishing chromatography steps in downstream processing, such as ion exchange (IEX) and hydrophobic interaction chromatography (HIC) for impurity removal.
Viral clearance validation strategies, including low pH viral inactivation and nanofiltration techniques in biopharmaceutical manufacturing.
Continuous bioprocessing paradigms, such as multi-column periodic counter-current chromatography (PCC) and integrated continuous downstream lines.
Regulatory standards (FDA/EMA guidelines) and Quality by Design (QbD) frameworks for process validation and analytical characterization of therapeutic proteins.
8.9K views170likes13:24@MarloesPeetersOriginal Release: 2022-12-22

Downstream processing of monoclonal antibodies involves a multi-step purification workflow including clarification (centrifugation/filtration to remove cells and debris), protein A affinity chromatography (high-selectivity purification targeting the antibody's Fc region), low pH viral inactivation/elution, polishing chromatography steps, and final viral clearance filtration; key considerations include product stability during processing, cost drivers (protein A resin accounts for ~50% of DSP costs), quality control through critical quality attribute monitoring, and emerging trends toward continuous processing and single-use technologies.